Demographics and Disease Associations of Patients with Monkeypox and Recipients of Monkeypox Vaccine from Safety Net Hospitals in New York City: A Cross-Sectional Study

Published: 24 October 2022| Version 1 | DOI: 10.17632/6dbwp3kxyr.1
Abigail Cline,


Supplementary Table 1. Monkeypox Cases. Inclusion criteria included all patients presenting to the NYC HHC system between 2/17/2022 and 8/16/2022 with either lab component: ORTHOPOXVIRUSPCR: Abnormal and Final or ORTHOPOXVIRUS DNA: Abnormal and Final AND Confirmed Diagnosis of HIV or Chief Complaint of Rash or Treatment with Tecovirimat, TECOVIRIMAT 200 MG PO CAPS, TECOVIRIMAT 200 MG/20ML IV SOL



Dermatology, Public Health